Radiopharm Theranostics (ASX: RAD, Nasdag: RADX"Radiopharm" or the “Company"), a clinical-stage biopharmaceutical company focused on developing innovative on cology radiopharmaceuticals for areas of high unmet medical need, announced that the U.S. food and Drug Administration (FDA) has provided clearance of the Company's Investigational New Drug (IND) application for Betabart (RV-01), its Lu177-B7H3 monoclonal antibody designed with strong affinity for the 4lg isoform of B7H3 that is highly expressed in tumors and not in healthy tissues.

AsymBio, a strategic partner of Radiopharm Theranostics, extended its warm congratulations on the major milestone for Betabart (RV-01). The collaboration leveraged AsymBio’s industry-leading CDMO platform for Novel Drug Conjugates (NDCs) to complete CMC studies for IND submission. AsymBio looks forward to joint efforts with Radiopharm Theranostics to address critical unmet medical needs for patients worldwide.